Outset Medical adds former Stryker leader as new EVP of commercial
Outset Medical has appointed Derick Elliott, formerly of Stryker and Cardinal Health, as its new Executive Vice President of Commercial. Effective immediately, Elliott will oversee the company's commercial organizations supporting acute, post-acute, and home healthcare providers. His extensive experience in medtech sales and marketing, including his previous role as CCO at SpendMed, aligns with Outset Medical's strategy for its portable hemodialysis system, Tablo.
Outset Medical names Derick Elliott commercial chief By Investing.com
Outset Medical, Inc. (NASDAQ:OM) has appointed Derick Elliott as Executive Vice President of Commercial, effective immediately. Elliott brings over 30 years of sales and marketing experience from Stryker, Cardinal Health, and SpendMend, and will be responsible for overseeing the company's commercial organizations. The company's stock has seen an 11% gain in the past week, and InvestingPro analysis suggests it may be undervalued.
BD Rolls Out Next-Gen Medication Dispensing System Across Europe
BD has launched its BD Pyxis Pro Dispensing Solution and BD Incada Connected Care Platform in Europe, combining automation with AI-powered insights to enhance medication management, streamline workflows, and improve patient care. This system aims to boost operational efficiency and medication availability across European hospitals. Despite a recent stock dip, the company expects this move to strengthen its competitive position in the digital healthcare sector due to increased demand for its innovative solutions.
Assessing McKesson (MCK) Valuation After Upward Earnings Revisions And Strength In Pharmaceutical Distribution
McKesson (MCK) is currently valued at US$884.28 and appears undervalued with a narrative fair value of approximately US$997.67, according to Simply Wall St. Recent upward earnings revisions and its strong performance in exceeding EPS estimates, coupled with benefits from a complex pharmaceutical supply chain, contribute to its positive outlook. Investors are advised to consider both the rewards and risks, such as potential tighter drug pricing regulations, before making investment decisions.
Longtime supervisor sues Cardinal Health over age and gender bias
A 65-year-old supervisor, Robert Jeffrey Mason, is suing Cardinal Health for age and gender discrimination, alleging he was fired after a brief investigation into routine supervisory conduct. Mason claims he was terminated based on complaints from a new, younger female employee that he says were mischaracterized or taken out of context. He argues that a female supervisor acting similarly would not have been fired, highlighting a growing tension for HR teams in handling workplace complaints without creating new liabilities.
Global Clinical Drainage Supplies Market Dominated by North America as Cardinal Health and Medline Expand Products
The global clinical drainage supplies market is transitioning to a critical infrastructure layer in healthcare, valued at USD 4.5 billion in 2026 and projected to reach USD 8.8 billion by 2036 with a CAGR of 6.9%. Growth is driven by standardization, infection control, and the expansion of integrated kits, with North America dominating and India emerging as the fastest-growing market. Key players like Becton, Dickinson and Company, Cardinal Health, Medtronic, Teleflex, and Getinge compete on portfolio coverage and supply continuity.
Global Clinical Drainage Supplies Market Dominated by North America as Cardinal Health and Medline Expand Products
The global clinical drainage supplies market is projected to grow from USD 4.5 billion in 2026 to USD 8.8 billion by 2036, at a CAGR of 6.9%. This growth is driven by the increasing need for protocol standardization and infection control in surgical and post-acute care, with reliability and seal integrity being key factors for procurement. North America, alongside emerging markets like India and Brazil, is a significant driver of this expansion, while key players such as Becton, Dickinson and Company, and Cardinal Health continue to dominate.
Cencora Expands Retina Network As CFO Retirement Opens New Chapter
Cencora (NYSE:COR) has announced a binding agreement to acquire the retina division of EyeSouth Partners, aiming to reinforce its presence in ophthalmology-focused healthcare. Concurrently, the company's CFO, James F. Cleary, plans to retire by June 2026, prompting an executive search for his successor. These strategic moves—the acquisition to expand specialty care and the leadership transition—are set to shape Cencora's future direction in healthcare services.
Cencora Expands Retina Network As CFO Retirement Opens New Chapter
Cencora (NYSE:COR) is expanding its specialist healthcare offerings by acquiring the retina division of EyeSouth Partners, integrating it into its Retina Consultants of America network. This strategic move aims to strengthen its position in higher-complexity eye care services. Concurrently, CFO James F. Cleary announced his retirement, effective June 30, 2026, marking a leadership transition that investors will watch closely regarding capital allocation and financial strategy.
Tema Etfs LLC Trims Cardinal Health Stock Position
Tema Etfs LLC, a major institutional investor, reduced its stake in Cardinal Health, Inc. by 32.1% in the fourth quarter, selling 4,786 shares and now owning 10,119 shares valued at $2,079,000. This move signals a potential shift in market sentiment or confidence regarding the healthcare distribution company, prompting other investors to observe if this is an isolated incident or a trend. Cardinal Health is a multinational company specializing in pharmaceutical distribution, medical-surgical product supply, and logistics.
Do Earnings Revisions And Value-Based Care Momentum Change The Bull Case For McKesson (MCK)?
McKesson (MCK) has seen positive earnings estimate revisions and consistent EPS beats, driven by its pharmaceutical distribution and growing role in value-based care. While these factors support a strong near-term outlook, potential risks related to drug pricing policy remain significant. The company's future performance will depend on its ability to leverage its scale and services amidst regulatory pressures, with current forecasts projecting a substantial increase in revenue and earnings by 2029.
Cardinal Health Increases Ac-225 Production to Enhance Cancer Treatment Options
Cardinal Health has significantly increased its Actinium-225 (Ac-225) production capacity at its Indianapolis facility to support growing clinical trials and future commercial demand for cancer therapies. This strategic expansion solidifies its position in the radiopharmaceutical sector and is expected to drive long-term revenue growth. The company's stock has performed positively this year, outperforming the medical and dental supplies industry and the S&P 500, and it holds a Zacks Rank #2 (Buy).
Cardinal Health Increases Ac-225 Production to Enhance Cancer Treatment Options
Cardinal Health has significantly increased its Actinium-225 (Ac-225) production capacity at its Indianapolis facility to support the growing demand for advanced cancer treatments, particularly radiopharmaceuticals. This expansion aims to meet the needs of ongoing clinical trials and prepare for future commercialization, strengthening Cardinal Health's position as a key supplier in the rapidly expanding oncology market. The company's strategic move is expected to drive consistent revenue growth and a stronger competitive edge, coinciding with a positive outlook for the cancer gene therapy market.
Here’s why investing in NeuroPace shares could be a smart addition to your portfolio at this time
NeuroPace, Inc. shows strong growth potential due to robust RNS technology adoption, expanding referral networks, and the integration of AI solutions, plus a significant long-term opportunity with its pursuit of an indication for idiopathic generalized epilepsy (IGE). While short-term profitability may be affected by increased investments and seasonal trends, the company's core RNS business is expected to drive near-term growth, with forecasts of 20%-22% annual growth. Investor sentiment is further supported by analyst upgrades and consistent earnings beats.
Here’s why investing in NeuroPace shares could be a smart addition to your portfolio at this time
NeuroPace, Inc. is positioned for growth thanks to strong adoption of its RNS technology, expansion into new indications like idiopathic generalized epilepsy (IGE), and integration of AI solutions. While significant investments and the uncertain timeline for IGE-related revenue may affect short-term profitability, the company's core RNS business is expected to drive near-term growth. Analysts have improved their sentiment for 2026, narrowing the loss-per-share estimate.
Here's Why You Should Add NeuroPace Stock to Your Portfolio Now
NeuroPace (NPCE) shows strong growth potential due to its RNS system adoption, expanding referral networks, and AI innovations, with an average earnings surprise of 24.7%. Despite near-term profitability pressures from investments and seasonality, the company's potential expansion into idiopathic generalized epilepsy (IGE) and advanced AI tools are expected to drive significant long-term growth. The article recommends adding NeuroPace stock, currently a Zacks Rank #2 (Buy), to portfolios.
Cardinal Health Increases Ac-225 Production to Enhance Cancer Treatment Options
Cardinal Health has significantly expanded its Actinium-225 (Ac-225) manufacturing capabilities to meet growing demand for radiopharmaceuticals in cancer treatment. This move strengthens its position as a key supplier for clinical trials and prepares the company for future commercial needs. The expansion builds on previous increases and is expected to drive consistent revenue growth by establishing long-term partnerships with pharmaceutical developers.
HF Advisory Group LLC Buys 5,049 Shares of Cardinal Health, Inc. $CAH
HF Advisory Group LLC significantly increased its stake in Cardinal Health (CAH) by 97.5% in Q4, acquiring 5,049 additional shares, bringing its total holdings to 10,227 shares valued at $2.102 million. This comes as Cardinal Health has received "Moderate Buy" ratings from analysts, with a consensus price target of $245.67, and beat its recent quarterly earnings expectations with an EPS of $2.63 and revenue of $65.63 billion. The company also announced a quarterly dividend of $0.5107.
Kwmg LLC Has $16.51 Million Position in Cardinal Health, Inc. $CAH
Kwmg LLC has reduced its stake in Cardinal Health (CAH) by 22.6% to 80,317 shares, valuing its position at $16.51 million, yet CAH remains its 21st-largest holding. Cardinal Health recently surpassed Q4 earnings and revenue estimates, reporting $2.63 EPS on $65.63 billion revenue, and declared a $0.5107 quarterly dividend. Analysts maintain a "Moderate Buy" consensus with an average price target of $245.67.
Can CAH’s Unique Specialty Flywheel Approach Drive Sustainable Growth Over Time?
Cardinal Health (CAH) is implementing a comprehensive specialty strategy that integrates distribution, MSO platforms, and biopharma services to drive growth. This "specialty flywheel" positions CAH to capture a larger market share and sustain earnings growth, similar to strategies adopted by industry peers like McKesson and Cencora. CAH's stock has outperformed the industry year-to-date, and analysts project significant earnings growth for fiscal 2026.
Cardinal Health Deepens Actinium-225 Role As Board Leadership Shifts
Cardinal Health is expanding its Actinium-225 production capacity for cancer treatment, positioning itself for clinical trials and commercial manufacturing globally. This development coincides with the appointment of Patricia A. Hemingway Hall as the new Chair of the Board, signaling a focus on both operational capabilities and governance following a company transformation. The move strengthens Cardinal Health's role in the specialized nuclear medicine supply chain, offering potential long-term contract relationships if targeted alpha therapies gain wider clinical use, though it also introduces risks related to scaling complex operations and reliance on trial outcomes.
Cardinal Health, Shine Technologies amp up domestic production of radiopharmaceuticals
Cardinal Health is expanding its domestic production of actinium-225, a radiopharmaceutical used in cancer treatment, at its Indianapolis facility. This expansion aligns with a federal push for US-produced drugs, as the US typically relies on overseas reactors for critical radiopharmaceuticals. Additionally, one of Cardinal's suppliers, Shine Technologies, has begun exporting its medical isotope lutetium-177 from Wisconsin.
WST Expands Dublin Facility to Boost Injectable Therapy Capacity
West Pharmaceutical Services (WST) has expanded its Dublin facility with a new 165,000 square foot building to meet the rising global demand for high-volume injectable therapies, especially for chronic diseases like diabetes and obesity. This expansion enhances WST's contract manufacturing capabilities under its West Vantage platform, offering end-to-end development support and strengthening its position in the injectable drug delivery market. Following this news and strong Q4 2025 results, the company expects sustained growth and improved long-term value.
Here's Why You Should Retain IRTC Stock in Your Portfolio for Now
iRhythm Holdings (IRTC) is positioned for strong growth due to robust volume, primary care expansion, and EHR integration, supported by investments in AI and clinical validation. However, the company faces potential challenges from reimbursement issues, regulatory pressures, and increasing competition. Despite these headwinds, iRhythm's strong market position and innovative approach suggest reasons to retain its stock.
Can CAH's Specialty Flywheel Strategy Unlock Long-Term Growth?
Cardinal Health's "specialty flywheel" strategy, integrating distribution, MSO platforms, and biopharma services, is projected to drive long-term growth by creating an interconnected ecosystem. This approach enhances manufacturer partnerships, streamlines product launches, and expands patient access, positioning Cardinal Health to capture a larger share of the specialty value chain. Peers like McKesson and Cencora are adopting similar strategies, indicating a broader industry shift towards specialty drugs and services as a key growth driver.
Can CAH's Specialty Flywheel Strategy Unlock Long-Term Growth?
Cardinal Health (CAH) is implementing a "specialty flywheel" strategy that integrates distribution, MSO platforms, and biopharma services to drive long-term growth. This approach creates a unified ecosystem that enhances credibility with manufacturers and secures recurring revenue streams. Other major distributors like McKesson (MCK) and Cencora (COR) are also focusing on similar integrated specialty strategies to capitalize on high-margin opportunities and long-term earnings expansion.
Reasons to Retain DENTSPLY SIRONA Stock in Your Portfolio Now
DENTSPLY SIRONA (XRAY) is positioned for growth due to new digital-implant workflows and increased investment in research and development, despite facing headwinds from forex fluctuations and soft European demand. The company plans double-digit increases in R&D, expands its dealer network, and implements cost restructuring to reallocate funds toward debt reduction and share repurchases. However, near-term revenue decline, margin pressure from tariffs, and weakness in core segments like implants and orthodontics remain concerns for the company.
Emerging Sub-Segments Transforming the Intravascular Catheterization Market Landscape
The intravascular catheterization market is projected to reach $18.83 billion by 2030, growing at a CAGR of 6.8%, driven by advancements in medical technology, demand for minimally invasive techniques, and focus on infection prevention. Key trends include the adoption of advanced catheters, infection-resistant materials, and AI-powered imaging systems. Major players are expanding their market presence through strategic acquisitions and continuous innovation in catheter design and monitoring.
Cardinal Health expands Actinium-225 production capacity to support growing demand for novel cancer therapies
Cardinal Health has significantly expanded its Actinium-225 (Ac-225) production capabilities at its Center for Theranostics Advancement in Indianapolis. This move aims to meet the growing global demand for Ac-225, a critical component in novel targeted alpha therapies for various cancers. The company has quadrupled its weekly output since late 2024 and plans further increases in 2026, supporting clinical trials and preparing for future commercial manufacturing.
Cardinal Health expands Actinium-225 production capacity to support growing demand for novel cancer therapies
Cardinal Health has significantly expanded its Actinium-225 (Ac-225) production capabilities at its Center for Theranostics Advancement in Indianapolis, Indiana, by adding a high-capacity production line. This expansion will meet the growing global demand for cGMP-compliant Ac-225, a critical alpha-emitting radionuclide used in novel cancer therapies. The company has quadrupled its weekly output since late 2024 and expects further increases, supporting numerous clinical trials and preparing for future commercial volumes of targeted alpha therapies.
Cancer drug developers get more Actinium-225 as Cardinal Health expands
Cardinal Health (NYSE:CAH) has significantly expanded its Actinium-225 (Ac-225) production capacity at its Center for Theranostics Advancement in Indianapolis, quadrupling weekly output since late 2024. This expansion aims to meet the growing demand for novel targeted alpha cancer therapies, having already supported over 15 clinical trials worldwide. The company plans further capacity increases in 2026 to facilitate both clinical development and future commercial manufacturing of these critical oncology treatments.
Brookstone Capital Management Increases Stake in McKesson Corporation $MCK
Brookstone Capital Management raised its stake in McKesson Corporation by 18.8% in Q4, now owning 13,821 shares valued at $11.34 million. McKesson exceeded Q4 earnings expectations with an EPS of $9.34 and revenues of $106.16 billion, also providing strong FY2026 EPS guidance. Despite some insider selling, institutional investors own 85.07% of the stock, and analysts maintain a "Moderate Buy" rating for the company.
Cardinal Health Inc Stock: Dividend Payout and Strategic Position in Healthcare Distribution Ahead of Q3 Earnings
Cardinal Health Inc (CAH) has a compelling investment case as it goes ex-dividend on April 1, 2026, offering a $0.5107 quarterly dividend. The company boasts robust growth in pharmaceutical distribution and consistent dividend increases for 39 consecutive years. With its strategic position in healthcare distribution and strong financial performance, including surpassing Q2 revenue and EPS expectations, Cardinal Health presents a balanced risk-reward profile for North American investors ahead of its Q3 earnings report on April 30.
Is Cardinal Health (CAH) Still Attractive After Recent Pullback And Strong Multi Year Gains
Cardinal Health (CAH) has seen strong multi-year gains despite a recent pullback and is currently trading at around US$211 per share. A Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 57.4%, with an implied intrinsic value of $495.89 per share. While its P/E ratio of 29.92x is above the industry average, Simply Wall St's proprietary Fair Ratio of 33.48x indicates that the shares still appear undervalued based on earnings.
Can CAH’s Unique Specialty Flywheel Approach Drive Sustainable Growth Over Time?
Cardinal Health (CAH) is implementing a "specialty flywheel" strategy, integrating distribution, MSO platforms, and biopharma services to drive sustainable growth. This approach creates a positive feedback loop, enhancing relationships with manufacturers and providers while expanding patient access. Its industry peers, McKesson (MCK) and Cencora (COR), are adopting similar strategies, and Cardinal Health's stock performance and earnings outlook are strong, earning it a Zacks Rank #2 (Buy).
Cardinal Health, Inc. (NYSE:CAH) Short Interest Up 21.1% in March
Cardinal Health (NYSE:CAH) experienced a 21.1% increase in short interest during March, with 6,045,787 shares sold short as of March 13th. Analysts maintain a "Moderate Buy" rating with an average target price of $245.67. The company also reported strong quarterly earnings, beating expectations, and declared a dividend of $0.5107.
Factors Supporting the Continued Inclusion of DENTSPLY SIRONA Shares in Your Investment Portfolio
Dentsply Sirona (XRAY) is positioned for growth due to its innovative digital implant solutions and increased R&D investments, despite facing challenges like unfavorable currency exchange rates and weak European demand. The company is expanding dealer partnerships and optimizing costs for long-term benefits, but short-term revenue pressures and margin compression are expected in 2026. While analysts project a revenue decrease and lower EPS for 2026, the article suggests it's a hold with potential for future improvement.
FMC Corporation (FMC) latest stock news and headlines
This article provides a compilation of recent news and headlines concerning FMC Corporation (FMC), including updates on stock performance, upcoming earnings calls, and analyst valuations. It highlights the company's stock movements, dividend declarations, and strategic announcements, offering investors a snapshot of its recent activities and market sentiment.
CVS Specialty delivers personalized care through 30+ Centers of Excellence
CVS Specialty leverages over 30 condition and therapy-specific Centers of Excellence (CoEs) to provide personalized care for patients with complex, rare, and ultrarare conditions. These CoEs feature specially trained CareTeams, deep clinical expertise, and systems to ensure medication access and support for unpredictable patient needs, as highlighted by the case of a young hemophilia patient. The model aims to simplify care by addressing the unique challenges and varying needs of patients within a broad spectrum of chronic conditions.
Cardinal Health Inc. stock rises Tuesday, still underperforms market
Cardinal Health Inc. (CAH) shares rose 2.42% to $211.31 on Tuesday, ending a three-day losing streak. Despite the gain, the stock underperformed the broader market, which saw the S&P 500 Index and Dow Jones Industrial Average advance by 2.91% and 2.49% respectively.
Baxter International Introduces IV Verify to Improve the Precision of IV Labeling
Baxter International has launched its IV Verify Line Labeling System, an automated platform designed to enhance precision in IV medication labeling and reduce errors in clinical settings. This system uses barcode scanning and instant printing for clear, three-part adhesive labels, aiming to improve patient safety and nurse productivity. This innovation aligns with a growing global intravenous solutions market, providing an opportunity for Baxter to expand its market presence and generate recurring revenue.
Global Helium-Free MRI Scanners Market to Reach USD 4.2 Billion by 2036, Driven by Siemens Healthineers, Philips, and GE Healthcare Innovation
The global helium-free MRI scanners market is projected to grow from USD 1.8 billion in 2026 to USD 4.2 billion by 2036, at a CAGR of 8.8%. This growth is driven by increasing demand for sustainable imaging infrastructure, reduced operational costs, and simplified installation compared to traditional helium-dependent MRI systems. Siemens Healthineers, Philips, and GE Healthcare are key players innovating in this evolving market, with 1.5T systems dominating and hospitals being the leading end-users, especially in regions like India and China.
Baxter International Unveils IV Verify to Enhance IV Labeling Accuracy
Baxter International recently launched its IV Verify Line Labeling System, an automated solution designed to improve IV medication labeling and reduce errors in clinical settings. This system, developed in partnership with Vigilant Software, aims to address compliance gaps and enhance patient safety and nurse efficiency in hospitals. Despite a recent decline in stock performance, this innovation is expected to strengthen Baxter's infusion therapy ecosystem and capitalize on the growing intravenous solutions market.
Assessing Cencora (COR) Valuation After Recent Share Price Weakness And Premium P/E Ratio
Cencora (COR) has recently experienced share price weakness, with negative returns over the past week, month, and three months, despite strong longer-term performance. While Simply Wall St's narrative suggests the stock is 23.4% undervalued with a fair value of $407.92, its current P/E ratio of 37.4x is higher than the US Healthcare industry average, indicating a premium and less room for error if growth falters. Investors are encouraged to consider the full picture, including key rewards and warning signs, and explore other investment opportunities beyond Cencora.
Radiopharmaceutical Market Set to Boom Rapidly, Witnessing Strong Growth Through 2033 | Curium Pharma, Cardinal Health Inc., GE HealthCare Technologies Inc.
Coherent Market Insights has published a report forecasting significant growth in the radiopharmaceutical market through 2033, driven by evolving trends, technological innovation, and sustainability. The report provides a comprehensive analysis for business leaders, investors, and strategists, covering market trends, competitive dynamics, regional performance, and key players like Curium Pharma, Cardinal Health Inc., and GE HealthCare Technologies Inc. It segments the market by diagnostic and therapeutic types and applications such as oncology, cardiology, and neurology, emphasizing its role in the global economy and offering strategic insights for investment decisions.
Did Cardinal Health's (CAH) New Chair and Urology Deal Just Reframe Its Healthcare Partnership Strategy?
Cardinal Health recently appointed Patricia A. Hemingway Hall as the new Chair of its Board, succeeding Gregory B. Kenny. This leadership change, coupled with a recent urology-focused acquisition, is seen as continuity in the company's strategy to expand into higher-margin specialty businesses. The article suggests these moves are crucial for Cardinal Health to improve profitability amid thin margins and regulatory pressures, aiming for $317.2 billion in revenue and $2.6 billion in earnings by 2029 with a projected fair value of $249.60.
3M Company Stock: Diversified Industrial Leader Faces Legal Headwinds and Strategic Shifts in 2026
3M Company, a diversified industrial leader, is navigating ongoing legal challenges related to PFAS chemicals and earplugs while executing a strategy focused on core growth areas and portfolio optimization. The company's resilience is built on its diversified business model across safety, industrial, transportation, electronics, healthcare, and consumer segments, supported by strong brand recognition, an extensive patent portfolio, and a dividend aristocrat status. Despite legal headwinds and competitive pressures, 3M aims to capture secular trends in electrification, renewable energy, and advanced materials through innovation and financial discipline.
Henry Schein Inc Stock: A Steady Force in Dental and Medical Distribution for Long-Term Investors
Henry Schein Inc is presented as a stable investment in the dental, medical, and veterinary supplies distribution sectors. The company's diversified business model across these healthcare segments, its global reach, and integrated service offerings contribute to its strong market position and appeal to long-term investors. Despite potential macroeconomic pressures and competition, its essential role in healthcare delivery and focus on recurring revenue streams position it for predictable growth paths.
Henry Schein Inc Stock: A Steady Force in Dental and Medical Distribution for Long-Term Investors
Henry Schein Inc is presented as a stable investment in healthcare distribution, focusing on dental, medical, and animal health supplies. The company's diversified business model, global reach, and recurring revenue from consumables contribute to its resilience. It is seen as a suitable core holding for North American investors seeking defensive healthcare exposure with steady demand and growth potential.
Is It Time To Reassess McKesson (MCK) After The Recent Share Price Pullback?
McKesson (MCK) has experienced a recent share price pullback, declining 2.9% in the last week and 10.7% in the last month, though it maintains positive year-to-date and annual returns. A Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 42.0% with an estimated intrinsic value of $1,481.84 per share against a current price of $860. The company's P/E ratio of 24.3x is above the industry average but below its peer group, and Simply Wall St's proprietary Fair Ratio of 36.0x also indicates undervaluation.
